Skip to main content
Retour
IBRX logo

ImmunityBio, Inc.

Qualité des données : 100%
IBRX
NASDAQ Healthcare Biotechnology
7,42 €
▼ 1,99 € (-21,12%)
Cap. Boursière : 7,62B
Fourchette du Jour
6,54 € 9,15 €
Fourchette 52 Semaines
1,83 € 12,43 €
Volume
86 610 892
Moyenne 50J / 200J
7,10 € / 3,63 €
Clôture Précédente
9,40 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (627 pairs)

Métrique Action Médiane du Secteur
P/E -21,7 0,3
P/B 2,9
ROE % 3,7
Net Margin % -310,2 3,8
Rev Growth 5Y % 231,9 10,0
D/E 0,2

Objectif de Cours des Analystes

Hold
13,50 € +82.1%
Low: 12,00 € High: 15,00 €
BPA Prévisionnel
-0,26 €
CA Est.
210 M

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 1,96 €
1,20 € – 2,92 €
3,7 B 1
FY2029 1,09 €
0,67 € – 1,62 €
2,2 B 1
FY2028 0,51 €
0,40 € – 0,60 €
1,2 B 3

Points Clés

Revenue grew 231,86% annually over 5 years — strong growth
Negative free cash flow of -308,78M
PEG of 0,15 suggests growth is underpriced
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 436,45%
Capital efficient — spends only 3,39% of revenue on capex

Croissance

Revenue Growth (5Y)
231,86%
Revenue (1Y)668,31%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
N/A
ROIC-50,73%
Net Margin-310,18%
Op. Margin-226,00%

Sécurité

Debt / Equity
N/A
Current Ratio5,10
Interest Coverage-2,28

Valorisation

P/E Ratio
-21,69
P/B RatioN/A
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 668,31% Revenue Growth (3Y) 1249,57%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 231,86% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 113,29M Net Income (TTM) -351,40M
ROE N/A ROA -70,01%
Gross Margin 99,34% Operating Margin -226,00%
Net Margin -310,18% Free Cash Flow (TTM) -308,78M
ROIC -50,73% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 5,10
Interest Coverage -2,28 Dividend Yield 0,00%
Valuation
P/E Ratio -21,69 P/B Ratio N/A
P/S Ratio 67,29 PEG Ratio 0,15
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 7,62B Enterprise Value 8,41B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 113,29M 14,75M 622 000,0 240 000,0 934 000,0
Net Income -351,40M -413,56M -583,20M -416,57M -346,79M
EPS (Diluted) -0,38 -0,62 -1,15 -1,04 -0,89
Gross Profit 112,54M 14,75M 622 000,0 240 000,0 934 000,0
Operating Income -256,03M -344,18M -362,25M -351,30M -330,28M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 501,90M 382,93M 504,45M 362,36M 468,91M
Total Liabilities 1,00B 871,06M 1,09B 812,18M 712,82M
Shareholders' Equity -499,57M -489,10M -586,99M -447,33M -242,17M
Total Debt 878,12M 504,17M 726,72M 723,77M 645,66M
Cash & Equivalents 88,33M 143,43M 265,45M 104,64M 181,10M
Current Assets 314,88M 184,59M 294,08M 140,58M 334,35M
Current Liabilities 61,75M 54,94M 58,28M 500,86M 369,00M